Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel lactic acid bacteria and compositions containing them

A composition, lactic acid bacteria technology, applied in detergent compositions, medical preparations containing active ingredients, drug combinations, etc., can solve the problem of not describing the use of microorganisms and the like

Active Publication Date: 2014-01-08
ORGANOBALANCE MEDICAL AG
View PDF7 Cites 28 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the patent does not describe the use of microorganisms that have beneficial effects on the skin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel lactic acid bacteria and compositions containing them
  • Novel lactic acid bacteria and compositions containing them
  • Novel lactic acid bacteria and compositions containing them

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0152] In order to identify and select the microorganisms of the present invention, various strains from the Lactobacillus strain library were tested by a 4-step screening method, wherein they were first tested for their ability to micro-bind with pathogenic skin microorganisms (hereinafter also referred to as "target microorganisms") They (binding assay), and subsequently, the strains identified in the first step were tested on a microtiter plate scale in a coagglutination assay, in which coagglutination with the corresponding target organisms was qualitatively measured using a binocular stereomicroscope. In addition, coagulation was studied The strength of agglutination and the stability of binding to target microorganisms and the ability to prevent biofilms, which ultimately lead to the exemplary microorganisms (Lactobacilli) identified according to the present invention.

[0153] Combined analysis

[0154] In order to be able to quantify the binding activity of selected ...

Embodiment 2

[0165] coagglutination assay

[0166] The following validations in a volume of 0.8 mL and / or in 24-well plates were used to show the co-agglutination activity of the selected Lactobacillus strains.

[0167]In this method, the coagglutination behavior of the lactobacillus and the coagglutination behavior of the target strain are considered separately, and finally the coagulation action of the lactobacillus and the target strain mixed together is considered. This analysis was performed macroscopically and microscopically by using photographs of 24-well plates.

[0168] For these experiments, the target microorganism - Pseudomonas aeruginosa Monascus (DSMZ22644) and Staphylococcus aureus (DSMZ18587).

[0169] Lactobacillus strains were grown anaerobically in MRS medium at base 37 (deMan et al., 1960).

[0170] To make target microorganisms, after 16 hours, cells were harvested, washed 3 times with phosphate-buffered saline (PBS, pH 7.4) and adjusted to OD 600 =4.

[0171] ...

Embodiment 3

[0179] In addition, experiments were performed to show the effect of proteases on the Lactobacillus strains of the invention and their agglutination properties on target microorganisms.

[0180] The Lactobacillus strains and target strains of the invention were thus treated as described in Example 2.

[0181] The Lactobacillus strains of the invention were trypsinized with a protease (examples of proteases shown here). After treatment of the Lactobacillus strains, they were trypsinized at 37 for 60 minutes (12.4 units / mg, Sigma). Subsequently, the cells were washed twice again with PBS and the agglutination properties were quantified as described in Example 2.

[0182] These experiments have shown that after protease treatment, the Lactobacillus strains of the present invention have 50-76% of the target microorganism bacteria / target strain Pseudomonas aeruginosa and / or Staphylococcus aureus in a coagglutination assay of the target microorganisms. Agglutination. As examples ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a microorganism, of the order of lactic acid bacteria or analog, fragment, derivative, mutant or combination thereof. Said microorganism, or analog, fragment, derivative, mutants or combination thereof can be co-aggregated with at least Staphylococcus aureus or Pseudomonas aeruginosa.

Description

technical field [0001] The present invention relates to novel lactic acid bacteria, analogues or fragments thereof and compositions containing them, especially for use as probiotics and / or in physiological hygiene and therapy. In particular, the present invention relates to the use of novel lactic acid bacteria and / or compositions containing them for the treatment and / or prevention of all diseases which may be caused by Staphylococcus aureus or Pseudomonas aeruginosa. [0002] Furthermore, the developments described here provide novel bioproducts in the form of GRAS microorganisms lactic acid bacteria that can be used as antimicrobial additives with specific effects in the prevention and topical treatment of skin infections and in accelerating the healing of chronic wounds. [0003] Furthermore, the present invention relates to the use of a microorganism according to the invention or an analogue or a fragment thereof in a composition or a pharmaceutical product or a cosmetic p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N1/20C12R1/225A61K35/74A23L1/30A61K8/99A61K35/744
CPCA23V2002/00C12R1/225A61Q19/10A61K8/99C12N1/20C12Q1/04A61K35/747A61K35/744A61K35/74C11D3/381A23L1/3014A61Q17/005A23L33/135A61P17/00A61P17/02A61P17/04A61P17/06A61P17/08A61P17/16C12R2001/225C12N1/205A23V2200/08A23V2200/318A23V2200/3204A61K8/9728A61K2800/80
Inventor 克里斯丁·朗安德鲁斯·拉布帕特里克·戈勒茨
Owner ORGANOBALANCE MEDICAL AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com